Overview
Background: Human milk oligosaccharides (HMO) and microbiota are both key factors for infants to shape the gut flora and develop the immune system. Breastfed infant is beneficial to prevent the occurrence of infantile colic (IC) and atopic dermatitis (AD), which may through shaping a healthy microbiota. However, the gut microbiota biomarkers representing IC and AD have not yet been discovered. In addition, the effectiveness of supplement of HMO in infant formula reduce the incidence of IC and AD in infants is still debate.
Description
Purpose: To investigate the preventive role of HMO-supplement formula on IC and AD in term infants in a clinical trial.
Method: The investigators will enroll three cohorts (exclusive breastfeeding, formula feeding, and HMO-supplement formula feeding infants) for research. The investigators collected samples of serial baby feces from subjects at 0, 1, 2, 4, 6, 12 months in this study. The fecal microbiota composition will be analyzed by detecting 16S-rRNA using next generation sequencing method. The demographic data and incidence of IC (0-5 months) and AD (0-12 months) was followed and recorded.
Eligibility
Inclusion Criteria:
- New born
- Gestational age of >= 37 weeks
- birth weight greater than 2500 gm
Exclusion Criteria:
- Born with Perinatal insults
- Mother with antimicrobial agents 1 month before delivery
- Congenital abnormalities related to growth
- Major disease admitted to Level II or NICU